Twist Bioscience Corporation TWST R2K
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 22.8% over 5 years.
- Profit CAGR of 21.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TWST Twist Bioscience Corporation R2K | 66.87 | - | $4.16B | - | -24.75% | -18.16% | 22.76% | 21.45% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.31M | 6.17M | 6.54M | 11.49M | 13.56M | 13.60M | 17.16M | 19.30M | 21.21M | 28.16M | 31.20M | 35.02M | 42.02M | 48.13M | 56.11M | 54.24M | 60.18M | 63.74M | 71.50M | 75.30M | 81.46M | - | - | 92.79M | 96.06M | 99.01M | 103.70M | 110.72M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.77M | 44.76M | 48.17M | 49.73M | 53.59M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.03M | 51.30M | 50.84M | 53.97M | 57.12M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.59M | 81.42M | 80.77M | 87.07M | 95.78M |
| Operating Income | -16.75M | -16.62M | -17.49M | -22.90M | -26.26M | -28.12M | -55.83M | -32.09M | -28.20M | -32.79M | -38.00M | -42.12M | -55.94M | -60.80M | -61.16M | -44.63M | -61.64M | -60.78M | -46.98M | -48.89M | -88.92M | - | - | -41.56M | -30.12M | -29.93M | -33.10M | -38.66M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.16M | -24.05M | -23.93M | -26.91M | -32.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.00K | 24.00K | 143.00K | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.15M | 20.58M | -26.88M | -30.25M | -43.98M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 175.00K | 191.00K | 257.00K | 253.00K | 43.00K |
| Net Income | -16.94M | -16.87M | -17.62M | -22.64M | -25.93M | -27.92M | -55.64M | -31.77M | -28.21M | -32.90M | -37.92M | -40.04M | -45.56M | -60.67M | -60.52M | -41.82M | -59.16M | -57.40M | -43.01M | -45.49M | -85.57M | - | - | -39.33M | 20.39M | -27.14M | -30.51M | -44.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.78 | -0.82 | -0.91 | -1.13 | -1.08 | -0.74 | -1.04 | -1.01 | -0.75 | -0.79 | -1.47 | - | - | -0.66 | 0.33 | -0.45 | -0.50 | -0.71 |
| R&D Expense | 4.30M | 4.71M | 5.27M | 7.27M | 8.91M | 9.01M | 10.30M | 10.63M | 10.44M | 14.00M | 15.79M | 19.84M | 22.63M | 31.23M | 36.84M | 31.24M | 27.38M | 24.53M | 23.10M | 24.15M | 22.47M | - | 21.31M | 23.92M | 18.05M | - | 17.13M | 19.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.77M | 25.43M | 54.38M | 90.10M | - | 203.56M | 245.11M | 312.97M | 376.57M |
| Cost of Revenue | - | - | - | - | - | 119.33M | 155.38M | 179.62M | 185.57M |
| Gross Profit | - | - | - | - | - | 84.23M | 89.73M | 133.35M | 191.00M |
| Operating Expenses | - | - | - | - | - | 333.26M | 296.63M | 309.25M | 327.26M |
| Operating Income | -58.48M | -70.56M | -108.85M | -140.08M | - | -249.02M | -206.90M | -175.90M | -136.26M |
| EBITDA | - | - | - | - | - | -211.68M | -177.59M | -144.47M | -111.41M |
| Interest Expense | - | - | - | - | 367.00K | 80.00K | 5.00K | 29.00K | - |
| Pretax Income | - | - | - | - | - | -228.27M | -203.47M | -208.17M | -76.95M |
| Tax Provision | - | - | - | - | - | -10.41M | 1.15M | 560.00K | 719.00K |
| Net Income | -59.31M | -71.24M | -107.67M | -139.93M | - | -217.86M | -204.62M | -208.73M | -77.67M |
| Diluted EPS | - | - | - | -3.57 | - | -4.04 | -3.60 | -3.60 | -1.30 |
| R&D Expense | 19.17M | 20.35M | 35.68M | 43.01M | 69.07M | 120.31M | 106.89M | 90.85M | 80.28M |
Compounded Sales Growth
| 5 Years: | 22.76% |
| 1 Year: | 19.30% |
Compounded Profit Growth
| 5 Years: | 21.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +128.23% |
| 6 Months: | +114.95% |
| 3 Months: | +42.52% |
| 1 Month: | +17.94% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 115.79M | 186.99M | 398.88M | - | 961.38M | 776.40M | 614.32M | 641.86M |
| Current Assets | - | - | - | - | - | - | 596.48M | 424.26M | 346.78M | 332.97M |
| Cash & Equivalents | - | 31.23M | 80.76M | 46.73M | 93.67M | - | 378.69M | 286.47M | 226.32M | 183.05M |
| Inventory | - | - | - | - | - | - | 39.31M | 32.06M | 24.08M | 28.31M |
| Receivables | - | - | - | - | - | - | 40.29M | 44.06M | 34.90M | 57.02M |
| Total Liabilities | - | - | 26.73M | 34.91M | 62.62M | - | 171.99M | 152.97M | 141.63M | 168.90M |
| Current Liabilities | - | - | 18.54M | 30.35M | 36.03M | - | 90.66M | 73.32M | 71.01M | 91.41M |
| Long Term Debt | - | - | 7.22M | 4.40M | 1.40M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 94.91M | 94.07M | 85.03M | 75.57M |
| Total Equity | -76.61M | -133.36M | -201.42M | 152.08M | 336.26M | - | 789.38M | 623.43M | 472.69M | 472.96M |
| Shares Outstanding | - | - | - | - | - | - | 56.52M | 57.56M | 58.88M | 60.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.30M | -66.16M | -87.94M | -142.25M | - | -124.39M | -142.47M | -64.09M | -47.63M |
| Investing Cash Flow | -9.99M | 27.31M | -104.81M | -114.65M | - | -232.93M | 50.61M | -3.07M | -24.76M |
| Financing Cash Flow | 63.80M | 88.82M | 158.58M | 303.73M | - | 270.53M | 911.00K | 6.89M | 28.54M |
| Capital Expenditure | -6.59M | -3.69M | -14.76M | -9.87M | - | -101.86M | -27.78M | -5.08M | -28.00M |
| Free Cash Flow | -57.90M | -69.85M | -102.69M | -152.12M | - | -226.24M | -170.25M | -69.17M | -75.63M |
| Net Change in Cash | - | - | - | - | - | -86.78M | -90.95M | -60.27M | -43.85M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 41.4% | 36.6% | 42.6% | 50.7% |
| Operating Margin % | -543.2% | -277.5% | -200.1% | -155.5% | - | -122.3% | -84.4% | -56.2% | -36.2% |
| Net Margin % | -550.8% | -280.2% | -198.0% | -155.3% | - | -107.0% | -83.5% | -66.7% | -20.6% |
| ROE % | 44.5% | 35.4% | -70.8% | -41.6% | - | -27.6% | -32.8% | -44.2% | -16.4% |
| ROCE % | - | -72.6% | -69.5% | -38.6% | - | -28.6% | -29.4% | -32.4% | -24.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Artisan Partners Limited Partnership | 10.23% | 6.37M | $425.81M |
| 2 | ARK Investment Management, LLC | 10.19% | 6.34M | $424.14M |
| 3 | Blackrock Inc. | 8.92% | 5.55M | $371.42M |
| 4 | Edgepoint Investment Group Inc. | 8.64% | 5.38M | $359.93M |
| 5 | William Blair Investment Management, LLC | 8.46% | 5.27M | $352.39M |
| 6 | State Street Corporation | 5.89% | 3.67M | $245.46M |
| 7 | Vanguard Portfolio Management LLC | 4.25% | 2.65M | $177.15M |
| 8 | Vanguard Capital Management LLC | 4.24% | 2.64M | $176.47M |
| 9 | Invesco Ltd. | 3.49% | 2.17M | $145.23M |
| 10 | FMR, LLC | 3.04% | 1.89M | $126.38M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TWST